Cellzome Scientists Publish an Approach to Quantitative Proteomics in Nature Biotechnology
News Jan 09, 2007
In collaboration with the Institute of Systems Biology and the University of California, Los Angeles, Cellzome has mined its proteomic database to systematically investigate the physico-chemical principles governing mass spectrometric peptide sequencing.
Having generated this information, the team then developed software that enabled the genome wide prediction of so-called ‘proteotypic peptides’.
The use of proteotypic peptides can provide an approach to protein identification and to absolute protein quantification. This approach can therefore turn proteomics from a discovery tool into a quantitative biological science.
Tim Edwards, CEO of Cellzome, said: “This publication demonstrates once again the high scientific standard of our core research team. It illustrates one of the many ways in which we are exploiting our massive proteomic database: for the continuous improvement of our technology, for the benefit of our proprietary drug discovery projects, and for the benefit of our collaborations with leading pharmaceutical companies.”
GlaxoSmithKline plc (GSK) has launched a five-year, $67 million collaboration with the San Francisco and Berkeley campuses of the University of California to build a state-of-the-art laboratory. The goal is to use CRISPR technologies to explore how genes cause disease and to rapidly accelerate the discovery of new drugs.